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Abstract
Background: The 7.5 kb cryptic plasmid of Chlamydia trachomatis has been shown to be a virulence factor in
animal models, but its significance in humans still remains unknown. The aim of this study was to investigate the
prevalence and potential involvement of the C. trachomatis cryptic plasmid in causing various clinical
manifestations; including infertility, reproductive tract disintegrity, menstrual disorder, and polycystic ovarian
syndrome (PCOS) among genital C. trachomatis–infected patients.
Results: A total of 180 female patients of child bearing age (mean 30.9 years old, IQR:27–35) with gynecological
complications and subfertility issues, who visited Obstetrics and Gynecology clinics in Kuala Lumpur, Malaysia were
recruited for the study. Prevalence of genital chlamydial infection among these patients was alarmingly high at
51.1 % (92/180). Of the 92 chlamydia-infected patients, 93.5 % (86/92) were infected with plasmid-bearing (+) C.
trachomatis while the remaining 6.5 % (6/92) were caused by the plasmid-free (−) variant. Our data showed that
genital C. trachomatis infection was associated with infertility issues, inflammation in the reproductive tract
(mucopurulent cervicitis or endometriosis), irregular menstrual cycles and polycystic ovarian syndrome (PCOS).
However, no statistical significance was detected among patients with plasmid (+) versus plasmid (−) C. trachomatis
infection. Interestingly, plasmid (+) C. trachomatis was detected in all patients with PCOS, and the plasmid copy
numbers were significantly higher among PCOS patients, relative to non-PCOS patients.
Conclusion: Our findings show a high incidence of C. trachomatis infection among women with infertility or
gynecological problems in Malaysia. However, due to the low number of plasmid (−) C. trachomatis cases, a
significant role of the plasmid in causing virulence in human requires further investigation of a larger cohort.
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Background
Chlamydia trachomatis is a common bacterial sexually
transmitted disease (STD) worldwide. Chlamydial uro-
genital infection has increased at a fast rate, with more
than 2.8 million new cases diagnosed each year [1]. In
Malaysia, a high prevalence of chlamydial antibody was
detected among urban citizens [2], particularly young fe-
males and sex workers [3]. Long term asymptomatic per-
sistency of the pathogen among 50–70 % of individuals
results in wide spread of the disease [4], and leads to de-
layed treatment, which in turn causes prostatitis and epi-
didymitis in males or infertility in females [5]. In
females, the pathogen can ascend the reproductive tract
to the endometrial epithelium and fallopian tubes, lead-
ing to pelvic inflammatory disease (PID) in approxi-
mately 20–40 % of the infected patients; among which
11 % develop tubal factor infertility while 9 % show ec-
topic pregnancy [6]. C. trachomatis-mediated inflamma-
tion in the genital tract can result in cervicitis or
endometriosis, causing lesions, abnormal mucopurulent
discharge and thickening of the uterus inner layer [6].
Inflammation can also contribute to hormonal disorders,
i.e., polycystic ovarian syndrome (PCOS) and irregular
menses [7]. Additionally, newborn infants can be in-
fected at birth when delivered through an infected birth
canal, causing severe conjunctivitis or pneumonia [8].
In recent years, several research groups suggest that
the C. trachomatis without plasmid demonstrates a
weaker degree of virulence. The plasmid-deficient strains
show impaired ability to infect the female mouse genital
tract [9, 10]. C. trachomatis infection damages the repro-
ductive tract by activating TLR2 and initiates a Th1-
Fig. 1 Plasmid copy numbers among C. trachomatis-infected patients with different clinical parameters. Dot plot graphs show the ratio of
plasmid:Momp as determined by quantitative real-time PCR assay. Each dot represents data from a single patient in each group (n = 92). The
P values were measured with unpaired Student’s t-test. Data was considered significant when *P < 0.05. n.s.: non-significant
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dependent inflammatory response. In a study using
plasmid-cured C. muridarum mutant infection in a mur-
ine model, TLR2-dependent cytokine was not detected
and no sign of oviduct damage can be observed, suggest-
ing that the plasmid-cured mutant has lost virulence [9].
Also, intra-vaginal immunization of the plasmid-
deficient strains provide protection in the murine model
of genitourinary tract infection [11]; as well as in trach-
oma infected macaques [12] due to the failure to trigger
a Toll-like receptor 2-dependent immune response [13].
These findings have led to research on use of plasmid-
deficient strains as a potential human vaccine. In fact, an
intravaginal infection of attenuated plasmidless C. tra-
chomatis L2 has been shown to provide protection to
the host because it is nonpathogenic and raises systemic
antibody in the C3H/HeJ mouse model [11].
Despite compelling evidence in animal models, there
is no equivalent finding from human clinical study con-
firming the significance of plasmid in C. trachomatis in-
fection. A recent study in human ocular C. trachomatis
infection reveals that no direct association exists be-
tween plasmid copy numbers and disease severity [14].
Therefore, further work should be done to establish the
plausible connection. In this study, we investigated the
prevalence of plasmid-bearing (+) or plasmid-free (−) C.
trachomatis infection and the plasmid copy numbers
among obstetrics and gynecology patients in Kuala Lum-
pur, the capital city of Malaysia. By associating the data
with the patients’ clinical presentations, we evaluated the
prevalence and risk of plasmid (+) and plasmid (−) vari-
ants in affecting gynecological disorders.
Results
Demographics of the study population
The patient cohort from this study comprised 180 fe-
male patients of child-bearing age (mean: 30.95 years
old; IQR: 27–35) who visited the Obstetrics and
Gynecology clinic at the University of Malaya Medical
Centerfrom 2010 to 2014 (Table 1). A total number of
124 patients were married, 13 were single or had di-
vorced, and the remaining 43 patients did not reveal
their marital status. Most of the patients were of Malay
ethnicity (68.3 %), followed by Indians (13.3 %), Chinese
(12.7 %), and others (5.5 %), reflecting the demographics
of the multiethnic Malaysian population. A majority of
the patients recruited to the study presented with
gynecological complications or subfertility issues, and
had a higher risk of STD infection. The main reason for
Table 1 Patient demographics. Numbers (percentages) of patients with or without C. trachomatis infection; and patients infected
with plasmid (−) or plasmid (+) variants. n = 180. The P values for all variables were measured with Fisher’s exact test. For age,
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patients’ visit to the clinic was due to infertility (37 %).
Other reasons included abdominal pain, bleeding, menor-
rhagia, irregular menstrual cycles and others. Two patients
had cystectomy whereas one had a history of resolved PID.
C. trachomatis infection is associated with various
gynecological disorders
Genital C. trachomatis infection in each patient was
first diagnosed by detection of the C. trachomatis
Momp (OmpA) gene. Total DNA was first isolated
from the patients’ endocervical swabs and PCR ampli-
fied using a human β-globin control primer to ensure
the successful extraction of DNA from the endocervi-
cal swabs (data not shown). The presence of C. tra-
chomatis DNA was detected with Momp primer using
a nested PCR amplification method (outer primers
followed by inner primer amplification) [15]. The re-
sults were further confirmed using a quantitative real-
time PCR method with inner primer alone. MOMP is
expressed on the cell surface with a porin activity
that is often used for diagnosis of C. trachomatis
[16]. Over half of the patients, i.e., 51.1 % (92/180),
were diagnosed with genital C. trachomatis infection,
suggesting a high incidence of sexually transmitted
chlamydial infection among the female patients re-
cruited (Table 2). No significant difference was de-
tected among patients by age, marital status or ethnic
background. We then sequenced the Momp PCR
product and performed a nucleotide BLAST to assess
the diversity of C. trachomatis strains in the local
population. Interestingly, our data revealed that all samples
examined showed a D serotype (data not shown).
Overall, C. trachomatis infection showed an associ-
ation with infertility (OR:9.85, 95 % CI:4.70–20.63, P <
0.0001***) (Table 2). Among patients who were fertile,
only 32.1 % (36/112) were infected by C. trachomatis,
whereas among infertile patients, 82.4 % (56/68) had C.
trachomatis infection. Notably, a high C. trachomatis
prevalence of 90.7 % (39/43,) was detected among pa-
tients who were diagnosed with primary (1°) or second-
ary (2°) infertility (OR:20.580, 95 % CI:6.83–62.02, P <
0.0001***). Meanwhile, 68 % (17/25) of patients who ex-
perienced miscarriage were infected by C. trachomatis
(OR:4.486, 95 % CI:1.77–11.36, P = 0.0013**).
The inflammation (cervicitis with mucopurulent dis-
charge or endometriosis) of patients’ reproductive tract
was recorded by clinicians during examination. C. tra-
chomatis infection showed a close connection with the
inflammation in the reproductive system (OR:3.84, 95 %
CI:1.69–8.72, P = 0.0008***) (Table 2). Our data showed
that approximately 64 % (16/25) of patients who were
diagnosed with mucopurulent cervicitis (OR:2.167, 95 %
CI:0.90–5.23, P = 0.087) and 100 % (12/12) of patients
with endometriosis (OR:30.43, 95 % CI:1.77–524.2, P <
0.0001***) had C. trachomatis infection.
In addition, we showed that C. trachomatis infection
exhibited significant association with irregular menstrual
cycles (OR:2.07, 95 % CI:1.05–4.06, P = 0.045*) as well as
PCOS (OR:9.43, 95 % CI:1.17–76.14, P = 0.018*), when
compared to the uninfected controls.
Table 2 Chlamydial infection in patients with different symptoms. Numbers (percentages) of patients with or without C. trachomatis
infection. n = 180. The P values for all variables were measured with Fisher’s exact test. n.s.: non-significant
Parameters All patients (n = 180) Non-infected (n = 88) C. trachomatis-infected (n = 92) P value Odd Ratio (95 % CI)
Fertility
Fertile 112 76 (67.9 %) 36 (32.1 %)
Infertile 68 12 (17.6 %) 56 (82.4 %) <0.0001*** 9.852 (4.70 to 20.63)
- 1° or 2° infertility 43 4 (9.3 %) 39 (90.7 %) < 0.0001*** 20.580 (6.83 to 62.02)
- Miscarriage 25 8 (32.0 %) 17 (68.0 %) 0.0013** 4.486 (1.77 to 11.36)
Reproductive tract
Normal lining 143 79 (55.2 %) 64 (44.8 %)
Inflammation 37 9 (24.3 %) 28 (75.7 %) 0.00088*** 3.84 (1.69 to 8.72)
- Mucopurulent Cervicitis 25 9 (36.0 %) 16 (64.0 %) 0.0876 n.s. 2.167 (0.90 to 5.23)
- Endometriosis 12 0 (0.0 %) 12 (100.0 %) 0.0001*** 30.43 (1.77 to 524.2)
Menstrual Cycle
Regular 130 70 (53.8 %) 60 (46.2 %)
Irregular 50 18 (36.0 %) 32 (64.0 %) 0.0452* 2.074 (1.05 to 4.06)
Hormonal Disorder
Undiagnosed 170 87 (51.2 %) 83 (48.8 %)
PCOS 10 1 (10.0 %) 9 (90.0 %) 0.0184* 9.434 (1.17 to 76.14)
*P<0.05 **P<0.01 ***P<0.001
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Higher incidence of plasmid-bearing C. trachomatis
infection among patients with infertility, inflammation
and PCOS
Next, we investigated if the patients enrolled were in-
fected by plasmid (+) or (−) C. trachomatis variants.
Total DNA extracted from the vaginal swabs of the C.
trachomatis-infected patients were amplified with two
sets of cryptic plasmid primers (which target Pgp1 and
Pgp8 respectively) using quantitative real-time PCR ana-
lysis. Of the 92 C. trachomatis-infected patients, we de-
tected that 93.5 % (86/92) were caused by plasmid (+) C.
trachomatis whereas only 6.5 % (6/92) were caused by
plasmid (−) C. trachomatis (Table 1).
When comparing the clinical parameters of the pa-
tients, we noted no significant correlation between the
plasmid and the tendency for the patients to exhibit in-
fertility (OR:0.76, 95 % CI:0.13–4.40, P = 0.562), inflam-
mation (OR:5.26, 95 % CI:0.28–98.68, P = 0.155),
irregular menses (OR:2.81, 95 % CI:0.31–25.24, P =
0.315) and PCOS (OR:1.59, 95 % CI:0.08–30.6, P =
0.529) (Table 3). Among the patients with infertility,
92.8 % (52/56) cases were diagnosed with plasmid (+) C.
trachomatis, compared to only 7.14 % (4/56) cases with
plasmid (−) C. trachomatis. Similarly, the majority of the
patients who had inflammation in the reproductive tract
(96.4 %, 27/28) and PCOS (100 %, 9/9) were caused by
plasmid (+) C. trachomatis. Among the 6 patients in-
fected by plasmid (−) C. trachomatis, 2 were fertile while
4 had infertility. However, 5 among the 6 showed no
sign of inflammation and had regular menstrual cycles.
Higher relative plasmid copy numbers associated with
PCOS
To examine if the abundance of plasmid in C. trachoma-
tis is associated with the presence of the clinical symp-
toms, we quantified the plasmid copy numbers in each
patient (Figure 1). The average CT value from two cryp-
tic plasmid primers (Pgp1 and Pgp8) for each patient
was obtained. Relative plasmid copy numbers per bacter-
ium (ratio for plasmid:Momp) for all 92 C. trachomatis-
infected patients were calculated. In general, we noticed
no direct connection between fertility, the reproductive
tract lining and menstrual cycle, consistent with the pre-
vious studies in human ocular infection and in vitro tis-
sue tropism [14, 17]. Notably, PCOS patients showed a
higher plasmid copy number (2.386 ± 0.284 versus 1.734
± 0.096, P = 0.0472), relative to the non-PCOS patients.
Although endometriosis patients also demonstrated a
Table 3 C. trachomatis plasmid in patients with different symptoms. Numbers (percentages) of patients infected with plasmid (−) or
plasmid (+) C. trachomatis variants. n = 92. The P values for all variables were measured with Fisher’s exact test. n.s.: non-significant
Parameters C. trachomatis-infected
patients (n = 92)
Plasmid (−)
C. trachomatis (n = 6)
Plasmid (+)
C. trachomatis (n = 86)
P value Odd Ratio
(95 % CI)
Fertility
Fertile 36 2 (5.55 %) 34 (94.4 %)
Infertile 56 4 (7.14 %) 52 (92.8 %) 0.5629 n.s. 0.764
(0.13 to 4.40)
- 1° or 2° infertility 39 3 (7.6 %) 36 (92.3 %) 0.5295 n.s. 0.755
(0.14 to 3.95)
- Miscarriage 17 1 (5.8 %) 16 (88.2 %) 0.6939 n.s. 0.875
(0.09 to 8.01)
Reproductive tract
Normal lining 64 5 (7.8 %) 59 (92.1 %)
Inflammation 28 1 (3.5 %) 27 (96.4 %) 0.4045 n.s. 2.288
(0.25 to 20.55)
- Mucopurulent Cervicitis 16 0 (0.0 %) 16 (100 %) 0.1550 n.s. 5.269
(0.28 to 98.68)
- Endometriosis 12 1 (8.3 %) 11 (91.6 %) 0.5786 n.s. 0.733
(0.078 to 6.88)
Menstrual Cycle
Regular 60 5 (8.3 %) 55 (91.6 %)
Irregular 32 1 (3.1 %) 31 (96.8 %) 0.3153 n.s. 2.818
(0.31 to 25.24)
Hormonal Disorder
Undiagnosed 83 6 (72.2 %) 77 (92.7 %)
PCOS 9 0 (0 %) 9 (100 %) 0.5293 n.s. 1.59
(0.083 to 30.6)
Yeow et al. BMC Microbiology  (2016) 16:45 Page 5 of 9
comparatively higher plasmid copy number, (2.193 ±
0.308 versus 1.714 ± 0.110, P = 0.114), no statistical sig-
nificance was noted.
Discussion
In this study, we reported a high prevalence (51.1 %) of
C. trachomatis infection among female adults of child
bearing age, with subfertility or gynecological problems
who visited Obstetrics and Gynecology clinics in
Malaysia. This indicates that there is a pressing need for
wider population screening to increase awareness and
prevent the spread of the disease among the community.
Most of the patients who demonstrated symptoms were
diagnosed with genital C. trachomatis infection, includ-
ing infertility (82.4 %), reproductive system lesions
(75.7 %), irregular menses (64 %) and PCOS (90 %), sug-
gesting the C. trachomatis is a leading factor for female
reproductive system disorders.
Although a high rate of genital C. trachomatis preva-
lance was detected in our study, the patients recruited
were suspected to be at risk of the bacterial infection
based on the clinical examination. The rates of C. tra-
chomatis infection vary in different studies depending
on the group of patients recruited and the study region.
For example, a study using 50 infertile female patients
showed a 40 % infection rate by C. trachomatis [18]
whereas other studies reported only a 8 % [19] or 15 %
C. trachomatis infection rate. Among patients with tubal
infertility, the prevalence of C. trachomatis was reported
to be 38.3 % among 120 patients [20]. Consistent to the
previous study, the presence of plasmid (+) C. trachoma-
tis was high (93.5 %). However, the prevalence using
real-time PCR amplification depends highly on the assay
sensitivity. For data validation, a glycogen-positive test
for bacterial isolates can be used to confirm the presence
of plasmid in the bacteria [21].
Various research groups have established that the plas-
mid (+) C. trachomatis demonstrated a higher virulence
in animal models of ocular or genital infections [9–14].
Consistent with these findings, our results showed that
high percentages of those who had infertility (92.8 %),
inflammation in the reproductive tract (96.4 %), irregular
menses (96.8 %) and PCOS (100 %) were diagnosed with
plasmid (+) but not plasmid (−) variants of C. trachoma-
tis. Although these observations provide support for pre-
vious work which suggests the usage of plasmidless C.
trachomatis as a potential human vaccine [11], caution
must be taken as some of the patients who showed
symptoms were infected by the plasmid (−) strains. Also
note that the genetic diversity of human populations
may contribute to results contradicting experiments per-
formed using inbred animals. Therefore, additional sur-
veys which involve a larger human cohort should be
conducted to ensure the over-all safety of the plasmid-
less strains among individuals from diverse backgrounds.
Plasmid (+) or (−) C. trachomatis strains demonstrated
no difference with regards to growth kinetics, plaquing
efficiency and size but showed a defect in glycogen gran-
ule accumulation and intrainclusion movement [10]. A
recent study showed that C. trachomatis is capable of in-
ducing alteration to global host histone modifications
and double strand break repair, thus generating an envir-
onment favorable for malignant transformation [22]. In
fact, C. trachomatis infection poses risk for infected
individuals to develop cervix intraepithelial neoplasia
[23, 24], in a similar way to other tumor-inducing patho-
gens. Extra-chromosomal plasmid DNA may play a role
in integrating with the host genome which leads to this
pathological damage. The conserved 7.5 kb cryptic plas-
mid is a small, non-conjugative and non-integrative
extrachromosomal DNA that contains genes encoding 8
proteins [25]. The plasmid Pgp3 encodes for immunogenic
trimers which trigger specific antibody production in in-
fected individuals [26, 27]; and is secreted into the cytosol
of infected cells during chlamydial infection [28, 29]. Mean-
while, Pgp4 encodes for a protein which comprises a
putative helix-loop-helix domain which functions as tran-
scriptional regulator for virulence-associated genes [10, 30].
Therefore, expression of plasmid genes may be crucial in
leading to clinical symptoms. To support this notion, a
quantitative protein analysis could be carried out in the fu-
ture to measure the amount of plasmid-derived proteins in
the patient sample.
Conclusion
In conclusion, we suggest that plasmids maybe a poten-
tial risk factor for reproductive system disorders includ-
ing infertility, inflammation in the reproductive tract,
irregular menses and PCOS in genital chlamydial infec-
tion. However, continued work is required to substanti-




A total number of 180 female patients of child-bearing
age who visited the Obstetrics and Gynecology Out-
patient Clinics at the University of Malaya Medical
Centre voluntarily participated in the study from 2010
to 2014. Detailed clinical information on reasons for re-
ferral, gynecological history including menstruation,
symptoms of genital and urinary tract infection, obstetric
and medical histories were documented. The subjects’
vulva and cervix were examined for the presence of
lesions, warts, ulcers, ectopy, erythma and discharge.
Patients with a positive urine pregnancy test, recent
antibiotic therapy, yeast infection and genital tuberculosis
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were excluded from the study. The participants were
briefed that their blood and vaginal swab samples will
be used for research purposes, and written consent
was obtained. This study has been approved by the
University of Malaya Medical Centre Medical Ethics
Committee.
DNA extraction
Endocervical swabs were collected by using a Floqswab
(Copan, Brescia, Italy) and transferred to a laboratory in
a UTM-RT universal transport medium tube (Copan).
The samples were vortex mixed and the cells were cen-
trifuged at 400× g for 10 min. The cells recovered were
lysed and separated with phenol chloroform. The DNA
was precipitated using 1:10 volume of 3 M sodium acet-
ate and isopropanol at −20 °C overnight incubation. The
samples were washed and eluted with TE buffer.
PCR amplification
Diagnosis of C. trachomatis was performed as described
[15]. Nested PCR was performed to amplify the genes
that encode for Major Outer Membrane Protein
(MOMP) and plasmid using outer and inner primers
(Table 4). PCR samples were run in a Veriti Thermal Cy-
cler (Applied Biosystems, Essex, UK) at the following
conditions: 95 °C for 3 min, 30 cycles of 95 °C for 30 s,
50 °C for 1 min, and 72 °C for 1 min, followed by a final
extension at 72 °C for 7 min using HelixAmp Taq DNA
polymerase (Nanohelix, Daejeon, South Korea). The first
round PCR was amplified using 50 ng of DNA isolated
from endocervical swabs with outer primer pairs. Then,
1 μl of first round PCR product was used as the template
in the second round PCR and amplified with inner pri-
mer pairs. The amplicons were run on gel electrophor-
esis using 1.5 % agarose gel and viewed under a UV
transilluminator. Human β-globin gene was used as a
positive control to confirm successful DNA retrieval
from patient swabs. PCR amplification for human β-
globin primer was run separately in PCR master mix
containing a total volume 50 μl as follows: 1 μl template
DNA, 200 mM of each of dNTP, 25 pmol of each pri-
mer, 4 mM Tune Up solution, 5 μl of PCR buffer and
2.5 units of HelixAmp Taq DNA polymerase recombin-
ant (Nanohelix, Daejeon, South Korea). PCR samples
were run at the following conditions: 95 °C for 3 min,
30 cycles amplification consisted of 95 °C for 30 s, 50 °C
for 1 min, and extension at 72 °C for 1 min, followed by
final extension at 72 °C for 7 min.
Quantitative real-time PCR amplification
A quantitative real-time PCR assay was used to confirm
the diagnosis and to determine the plasmid copy num-
bers in patient samples. DNA samples isolated from the
vaginal swabs of C. trachomatis-infected patients were
prepared. Mastermix containing 1 μl template DNA, 1×
SsoAdvanced Universal SYBR Green Supermix (Biorad,
Hercules, CA), 10 pmol primers were run using a
Mx3000 Stratagene thermacycler (Agilent Technologies,
Santa Clara, CA). Primers used were inner primers for
Momp, inner primer for plasmid Pgp8, and plasmid Pgp1
primers. Plasmid copy number for each patient was cal-
culated as below:
Plasmid copynumber ¼ Average CTPgp1þ CTPgp8ð Þ
CTMOMP
Sequencing
Amplification of an approximately 871 bp fragment of
OmpA was performed by nested PCR. The first PCR step
Table 4 PCR primers used in C. trachomatis conventional PCR and real-time PCR diagnosis. For nested PCR amplification of Momp
and plasmid, outer primer pairs were used at first round PCR, while inner primer pairs were used at second round PCR amplification.
For real-time PCR diagnosis, Momp inner primer pairs, plasmid Pgp8 inner primer pairs and plasmid Pgp1 primer pairs were used
Target genes Primer Sequence (5′-3′) Amplicon size
Momp Outer forward TTGTTTTCGACCGTGTTTTG 455 bp
Outer reverse AGCRTATTGGAAAGAAGCBCCTAA
Inner forward AAACWGATGTGAATAAAGARTT 395 bp
Inner reverse TCCCASARAGCTGCDCGAGC
Plasmid Pgp8 Outer forward TTGGCYGCTAGAAAAGGCGATT 212 bp
Outer reverse TCCGGAACAYATGATGCGAAGT
Inner forward AACCAAGGTCGATGTGATAG 150 bp
Inner reverse TCAGATAATTGGCGATTCTT
Plasmid Pgp1 Forward TTCTTTGATGGCTTCCCAAC 456 bp
Reverse ACGATTTTCTCCAACCGATG
β-globin Forward GAAGAGCCAAGGACAGGTAC 268 bp
Reverse CAACTTCATCCACGTTCACC
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was carried out with outer primer pair (Table 1) using
10 μl of DNA extracted from swabs. Amplification was
performed in a final reaction volume of 50 μl containing
0.3 μM of each primer, 0.2 mM of dNTPs, 3 μl of
TuneUp solution (Nanohelix, Korea) and 5U of Helix-
Amp™Taq DNA polymerase (Nanohelix, Korea). The
first amplification conditions consisted of initial poly-
merase activation at 94 °C for 2 min; 40 cycles of 94 °C
for 45 s, 60 °C for 45 s and 72 °C for 90 s and a final
elongation step at 72 °C for 5 min. In the second round
PCR, 3 μl of product from the first PCR step was ampli-
fied using inner primer pairs (Table 1). Nested PCR con-
ditions consisted of 95 °C for 5 min; 40 cycles of 94 °C
for 1 min, 60 °C for 1 min and 72 °C for 2 min and a
final elongation step at 72 °C for 10 min. The amplified
products were visualized by electrophoresis on 1.5 %
agarose gel stained with GelRed solution (Biotium).
The 871 bp OmpA fragments obtained were purified
using a QIAquick Gel Extraction kit (Qiagen) and proc-
essed using a BigDye® Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA). The reaction
mixtures were loaded onto a 3730xL DNA Analyzers
(Applied Biosystems). The primers used for sequencing
were inner primer pairs. Nucleotide sequence data were
assembled by Bioedit and residues corresponding to
flanking primers were excluded from analysis. Sequences
were submitted to the standard nucleotide BLAST
search engine at the National Center for Biotechnology
Information (blast.ncbi.nlm.nih.gov/Blast.cgi) to determine
the genotype.
Statistical analysis
Statistical analysis was done using GraphPad PRISM ver-
sion 5. For normally distributed data, an unpaired t-test
was used. For categorical data (clinical symptoms), Fish-
er’s exact test was used, with a no-symptom group as
control. Odd ratio (OR) and 95 % confidence interval
(CI) were calculated. Statistical significance was deter-
mined at P < 0.05*, P < 0.01** and P < 0.001***.
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